Published in Lancet Oncol on April 24, 2009
Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer | NCT00105950
Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer (2010) 3.33
Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci Transl Med (2010) 2.42
Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res (2013) 1.80
Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat Rev Clin Oncol (2009) 1.67
The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin Cell Dev Biol (2010) 1.54
Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence. Br J Cancer (2011) 1.23
Targeting the HER/EGFR/ErbB family to prevent breast cancer. Cancer Prev Res (Phila) (2011) 1.21
Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. Breast Cancer Res Treat (2010) 1.19
Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. EMBO Rep (2015) 1.07
Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells. Cell Cycle (2015) 0.98
Lapatinib in combination with radiation diminishes tumor regrowth in HER2+ and basal-like/EGFR+ breast tumor xenografts. Int J Radiat Oncol Biol Phys (2010) 0.93
Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence. Am J Cancer Res (2015) 0.88
Molecular and epidemiological characteristics of inflammatory breast cancer in Algerian patients. Breast Cancer Res Treat (2011) 0.88
Novel therapies in breast cancer: what is new from ASCO 2008. J Hematol Oncol (2008) 0.88
A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer. Breast Cancer Res Treat (2012) 0.88
Anti-invasion, anti-proliferation and anoikis-sensitization activities of lapatinib in nasopharyngeal carcinoma cells. Invest New Drugs (2010) 0.87
Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells. MAbs (2013) 0.85
MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study. Oncotarget (2016) 0.83
Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer. Crit Rev Oncol Hematol (2010) 0.83
Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel. Wien Klin Wochenschr (2010) 0.82
Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival. Cancer Res (2016) 0.81
Lapatinib: new opportunities for management of breast cancer. Breast Cancer (Dove Med Press) (2010) 0.81
Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy. Clin Breast Cancer (2015) 0.80
Significance of Tyrosine Kinase Inhibitors in the Treatment of Metastatic Breast Cancer. Breast Care (Basel) (2009) 0.78
Developmental therapeutics for inflammatory breast cancer: Biology and translational directions. Oncotarget (2016) 0.77
HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status. Oncotarget (2016) 0.77
Lapatinib for inflammatory breast cancer. Lancet Oncol (2009) 0.76
Targeted treatment of advanced and metastaticbreast cancer with lapatinib. Onco Targets Ther (2008) 0.75
Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer. Invest New Drugs (2015) 0.75
Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine. PLoS Med (2016) 0.75
Everolimus enhances cellular cytotoxicity of lapatinib via the eukaryotic elongation factor-2 kinase pathway in nasopharyngeal carcinoma cells. Onco Targets Ther (2016) 0.75
Comparative analysis of evolutionarily conserved motifs of epidermal growth factor receptor 2 (HER2) predicts novel potential therapeutic epitopes. PLoS One (2014) 0.75
What is known about melatonin, chemotherapy and altered gene expression in breast cancer. Oncol Lett (2017) 0.75
Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res (2007) 16.79
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med (2011) 13.74
Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell (2004) 8.16
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med (2007) 7.05
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol (2004) 5.12
Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst (2005) 4.51
Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol (2004) 4.51
An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys (2007) 3.87
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol (2012) 3.75
Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist (2007) 3.42
Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res (2009) 3.31
Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol (2005) 3.18
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet (2009) 2.75
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol (2005) 2.70
Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat (2008) 2.65
Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res (2009) 2.51
HER-2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol (2008) 2.46
FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol (2012) 2.45
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol (2013) 2.39
Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res (2004) 2.34
Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol (2010) 2.34
Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res (2013) 2.09
Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res (2009) 2.08
Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol (2010) 2.03
Netrin-1 expression confers a selective advantage for tumor cell survival in metastatic breast cancer. Proc Natl Acad Sci U S A (2008) 1.95
Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. Lancet Oncol (2012) 1.91
Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist (2004) 1.88
Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol (2013) 1.79
Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol (2008) 1.78
Enumeration of circulating tumor cells in the blood of breast cancer patients after filtration enrichment: correlation with disease stage. Breast Cancer Res Treat (2004) 1.78
The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res (2005) 1.75
Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin Cancer Res (2006) 1.72
Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer. JAMA (2005) 1.68
Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res (2013) 1.68
Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist (2007) 1.61
Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys (2006) 1.60
Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected]. J Transl Med (2012) 1.59
Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res (2006) 1.58
A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. Eur J Cancer (2011) 1.51
Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol (2006) 1.47
Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen. Am J Clin Oncol (2003) 1.44
Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study. BMC Cancer (2013) 1.43
Will the dark sky over advanced renal cell carcinoma soon become brighter? Eur J Cancer (2005) 1.43
Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. Oncologist (2008) 1.41
The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer. Gynecol Oncol (2004) 1.41
Real-time functional magnetic resonance imaging neurofeedback for treatment of Parkinson's disease. J Neurosci (2011) 1.40
Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trial. BMC Cancer (2012) 1.40
Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol (2006) 1.40
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother (2008) 1.39
HER2/neu in systemic therapy for women with breast cancer: a systematic review. Breast Cancer Res Treat (2007) 1.38
Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. Oncologist (2010) 1.37
Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat (2014) 1.32
Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study. J Support Oncol (2007) 1.27
Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother Pharmacol (2007) 1.27
A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer. Cancer Invest (2008) 1.26
Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res (2012) 1.26
Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review. Cancer Treat Rev (2007) 1.26
Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers. Breast Cancer Res Treat (2009) 1.25
Early detection of tumor cells by innate immune cells leads to T(reg) recruitment through CCL22 production by tumor cells. Cancer Res (2011) 1.24
Time to disease recurrence in basal-type breast cancers: effects of tumor size and lymph node status. Cancer (2009) 1.24
Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation. Head Neck (2006) 1.23
ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells. Cancer Res (2012) 1.22
Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol (2013) 1.20
Results of a diet/exercise feasibility trial to prevent adverse body composition change in breast cancer patients on adjuvant chemotherapy. Clin Breast Cancer (2008) 1.19
A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies. Clin Cancer Res (2009) 1.18
Continuous intravascular secretion of endostatin in mice from transduced hematopoietic stem cells. Mol Ther (2002) 1.17
Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study. Eur J Cancer (2013) 1.17
Unfulfilled promise of endostatin in a gene therapy-xenotransplant model of human acute lymphocytic leukemia. Mol Ther (2002) 1.16
Lymphopenia: a new independent prognostic factor for survival in patients treated with whole brain radiotherapy for brain metastases from breast carcinoma. Radiother Oncol (2005) 1.16
Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study. Breast Cancer Res (2012) 1.16
Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients. Clin Cancer Res (2011) 1.15
Task-irrelevant visual motion and flicker attenuate the attentional blink. Psychon Bull Rev (2006) 1.12
Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics. Invest New Drugs (2009) 1.12
Mechanisms of resistance to aromatase inhibitors. J Steroid Biochem Mol Biol (2005) 1.11
Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series. Clin Breast Cancer (2009) 1.11
A candidate molecular signature associated with tamoxifen failure in primary breast cancer. Breast Cancer Res (2008) 1.10
Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer. Breast Cancer Res (2008) 1.09
New therapies for ovarian cancer: cytotoxics and molecularly targeted agents. Crit Rev Oncol Hematol (2008) 1.08
A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer. Clin Cancer Res (2011) 1.08
Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients. Oncoimmunology (2012) 1.05
Access to cancer drugs in Canada: looking beyond coverage decisions. Healthc Policy (2011) 1.05
Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02. Int J Radiat Oncol Biol Phys (2006) 1.05
Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients. Cancer Chemother Pharmacol (2008) 1.05
A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer. Int J Hyperthermia (2010) 1.04
Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes. Breast Cancer Res Treat (2011) 1.04
Bisphosphonate use for the management of breast cancer patients with bone metastases: a survey of Canadian Medical Oncologists. Support Care Cancer (2004) 1.04
IL-6 as an intracrine growth factor for renal carcinoma cell lines. Int J Cancer (2004) 1.02
αB-crystallin: a novel regulator of breast cancer metastasis to the brain. Clin Cancer Res (2013) 1.02
ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2. Endocr Relat Cancer (2008) 1.02
Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer. Clin Breast Cancer (2013) 1.01
Dynamic optimization of chemotherapy outpatient scheduling with uncertainty. Health Care Manag Sci (2014) 1.00
Diffuse optical spectroscopy evaluation of treatment response in women with locally advanced breast cancer receiving neoadjuvant chemotherapy. Transl Oncol (2012) 1.00
Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer. Oncologist (2008) 1.00
Breast carcinoma cells promote the differentiation of CD34+ progenitors towards 2 different subpopulations of dendritic cells with CD1a(high)CD86(-)Langerin- and CD1a(+)CD86(+)Langerin+ phenotypes. Int J Cancer (2004) 1.00
Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer. J Clin Oncol (2010) 0.99